Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy

  • Lun-Fei Liu University School of Medicine, The Second Affiliated Hospital, Department of Dermatology
  • Ji-Su Chen Zhejiang University School of Medicine, The Second Affiliated Hospital, Department of Dermatology
  • Ji-Yang Shen Ningbo Medical Center Lihuili Hospital, Department of Dermatology
  • Ting-Ting Dou Shan Dong Yan Tai Nursing School
  • Jiong Zhou Zhejiang University School of Medicine, The Second Affiliated Hospital, Department of Dermatology
  • Sui-Qing Cai Zhejiang University School of Medicine, The Second Affiliated Hospital, Department of Dermatology
  • Min Zheng Zhejiang University School of Medicine, The Second Affiliated Hospital, Department of Dermatology
Keywords: Psoriasis, Ustekinumab/efficacy, Biologic agents

Abstract

Psoriasis is a T-cell mediated disease that involves IL-23/Th17 and IL-12/Th1 axes. Ustekinumab, a fully human monoclonal antibody targeting the p40 subunit of both IL-12 and IL-23, has proven to be efficient and safe for treating patients with psoriasis. Yet, there have been no reports with human skin/blood samples that would elucidate the molecular mechanisms by which ustekinumab calms psoriasis skin lesions. To investigate the efficacy and molecular pathway (RORC, t-BOX and GATA) of ustekinumab in treating patients with psoriasis skin lesions. A total of 30 patients with psoriasis were randomized into placebo group and treatment group. PASI of each patient was calculated at 0, 12 and 24 weeks post-treatment. The mRNA levels of RORC, t-BOX and GATA in peripheral blood mononuclear cells separated from patients’ whole blood were analyzed using qPCR. Decreased mRNA of RORC, t-BOX and GATA were observed after continuous injections, indicating that ustekinumab exerts its effect by interacting with these molecules; while no significant difference in foxp3 mRNA levels were found between placebo group and treatment group.

Downloads

Download data is not yet available.
Published
2018-12-20
How to Cite
Liu, L.-F., Chen, J.-S., Shen, J.-Y., Dou, T.-T., Zhou, J., Cai, S.-Q., & Zheng, M. (2018). Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy. Brazilian Journal of Pharmaceutical Sciences, 54(4), e17349. https://doi.org/10.1590/s2175-97902018000417349
Section
Articles